Skip to main content

Highlights of Myeloma Rounds

Recorded on: January 12, 2024

Click Here to Participate

Recorded on: January 12, 2024
1.25 CME Credits for physicians available until: February 12, 2025
1.25 CPE Contact hour for pharmacists available until: February 12, 2025
1.25 CE Credit/Contact hours for nurses available until: February 12, 2025
Format: Non-interactive recorded webinar  

 

Target Audience

This activity is intended for hematologists-oncologists, medical oncologists, nurse practitioners, nurses and pharmacists involved in the care of patients with myeloma. 

Description

This webinar will feature highlights from three in-person Myeloma Rounds in Philadelphia, South Florida, and Winston-Salem that were held in the spring and fall of 2023, as well as highlights of additional clinical updates after the Rounds. Discussion will incorporate the latest developments in myeloma, including current and emerging therapies, clinical trials, strategies for optimal patient care, and application of evidence-based treatment strategies. Information on education and support resources for patients, caregivers, and healthcare professionals will also be provided. 

Educational Objectives

After completing this activity, the participant should be better able to:

  • Describe the latest developments in myeloma, including current and emerging treatments
  • Engage patients and caregivers in discussions on clinical trials, newly approved therapies and emerging therapies for myeloma, including combination therapies, CAR T-cell therapy and bispecific antibodies
  • Identify strategies for optimal patient care
  • Apply evidence-based treatment strategies
  • Access patient support resources

Faculty

Edward A. Stadtmauer, MD (Chair, Myeloma Rounds, Philadelphia)
Section Chief, Hematologic Malignancies
Roseman, Tarte, Harrow, and Shaffer Families’
President’s Distinguished Professor
University of Pennsylvania Abramson Cancer Center
Philadelphia, PA

Cindy Varga, MD (Chair, Myeloma Rounds, Winston-Salem)
Associate Professor
Atrium Health Levine Cancer Institute 
Plasma Cell Dyscrasia Division
Department of Hematology and Oncology
Charlotte, NC
 

Continuing Education Information

Accreditation, Credit and Support

In support of improving patient care, this activity has been planned and implemented by Medical Learning Institute, Inc., and The Leukemia & Lymphoma Society.  Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
Medical Learning Institute, Inc. (MLI) designates this enduring material activity for a maximum of 1.25 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Pharmacy Education
Medical Learning Institute, Inc. designates this continuing education activity for 1.25 contact hours (0.125 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA0007322-9999-24-016-H01-P   
Type of Activity: Application 

Registered Nursing Credit Designation
Approval for nurses has been obtained by the National Office of The Leukemia & Lymphoma Society under Provider Number CEP 5832 to award 1.25 continuing education contact hours through the California Board of Registered Nursing.

Nurse Practitioner Continuing Education
This education activity will be submitted to the American Association of Nurse Practitioners® for approval of up to 1.25 contact hours of accredited education. 

Interprofessional Continuing Education (IPCE) Statement

Interprofessional Continuing Education (IPCE) credit

This activity was planned by and for the healthcare team, and learners will receive 1.25 Interprofessional Continuing Education (IPCE) credits for learning and change.

Providers
This activity is supported in part by an independent educational grant from Bristol Myers Squibb. Additional funding provided by The Leukemia & Lymphoma Society.

 
For questions, concerns, or assistance for people with disabilities or grievances, please contact us at: profeducation@LLS.org.